The clinical application of glibenclamide: the problem of safety and efficacy

Well-timed, effective, and safe therapy of type 2 diabetes mellitus (DM2) is a challenging problem for public healthcare systems all over the world. Glibenclamide is currently the most popular sulfanylurea derivative prescribed to the patients presenting with DM2. High requirements to the safety profile of modern medications including oral hypoglycemic agents imply the necessity of close attention to the potential problems associated with the long-term application of glibennclamide. The present review is focused on the topical problems of safety and efficacy of glibenclamide arising from its use in the clinical practice.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.14341/PROBL201258365-69
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic Model of First-Line Drug Strategies to Achieve Recommended Glycaemic Control in Newly Diagnosed Type 2 Diabetes Mellitus

  2012cited by this paper
• Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

  2011cited by this paper
• The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy

  2010cited by this paper
• Glybenclamide: an antidiabetic with in vivo antithrombotic activity.

  2010cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Sulfonylureas Improve Outcome in Patients With Type 2 Diabetes and Acute Ischemic Stroke

  2007cited by this paper
• A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events

  2007cited by this paper
• Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study.

  2006cited by this paper
• Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular KATP channels

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Sulfonylurea Agents Exhibit Peroxisome Proliferator-activated Receptor γ Agonistic Activity*

  2005cited by this paper
• Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA).

  2003cited by this paper
• Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus

  2003cited by this paper
• Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.

  2003cited by this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cited by this paper
• Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels.

  2000cited by this paper
• Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues.

  2000cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Arrhythmias and Mortality After Myocardial Infarction in Diabetic Patients: Relationship to diabetes treatment

  1998cited by this paper
• Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulphonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade.

  1994cited by this paper

• No citing papers are available for this paper.